The IL-23/IL-17A pathway is a major target for psoriasis treatment and anti-IL-23/IL-17A agents are superior to anti-TNF agents in psoriasis.[23] Ustekinumab, binding to the P40 subunit of IL-12 and IL-23, has been approved for use in both diseases.[24] Risankizumab and mirikizumab, selective anti-IL-23 agents, were highly effective in psoriasis, and clinical trials are ongoing to evaluate the efficacy and safety of the anti-IL-23 agents in patients with IBD. This evidence concerns the gene IL17A and inflammatory bowel disease.